<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Azitra Inc — News on 6ix</title>
<link>https://6ix.com/company/azitra-inc</link>
<description>Latest news and press releases for Azitra Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 17:13:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/azitra-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7384251cc36e47532edb9.webp</url>
<title>Azitra Inc</title>
<link>https://6ix.com/company/azitra-inc</link>
</image>
<item>
<title>Azitra Announces Pricing of Private Placement Financing of up to Approximately $10.5 Million with up to an Additional Approximately $20.9 Million</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-announces-pricing-of-private-placement-financing-of-up-to-approximately-dollar105-million-with-up-to-an-additional-approximately-dollar209-million</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-announces-pricing-of-private-placement-financing-of-up-to-approximately-dollar105-million-with-up-to-an-additional-approximately-dollar209-million</guid>
<pubDate>Thu, 19 Mar 2026 17:13:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement (the "SPA") with new and existing healthcare focused institutional investors. The financing is for gross proceeds of up to approximately $31.4 million to the Company, including initial gross proceeds of approximately $10.5 million and up to an additional $20.9 million in gross</description>
</item>
<item>
<title>Azitra Receives Notice of Non-Compliance from NYSE American and Makes NYSE American Section 610(b) Public Announcement</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-receives-notice-of-non-compliance-from-nyse-american-and-makes-nyse-american-section-610b-public-announcement</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-receives-notice-of-non-compliance-from-nyse-american-and-makes-nyse-american-section-610b-public-announcement</guid>
<pubDate>Fri, 13 Mar 2026 21:15:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(iii) requires a listed company to have stockholders' equity of $6 million or m</description>
</item>
<item>
<title>Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-announces-cancellation-of-2026-special-meeting-of-stockholders-33</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-announces-cancellation-of-2026-special-meeting-of-stockholders-33</guid>
<pubDate>Thu, 05 Mar 2026 21:30:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR) ("Azitra" or the "Company"), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has cancelled the Company's special meeting of stockholders that was originally scheduled for February 6, 2026, but was adjourned due to a lack of quorum until March 6, 2026.</description>
</item>
<item>
<title>Azitra, Inc. Announces Full Year 2025 Results and Provides Business Updates</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-announces-full-year-2025-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-announces-full-year-2025-results-and-provides-business-updates</guid>
<pubDate>Fri, 27 Feb 2026 22:30:00 GMT</pubDate>
<description>Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2025, and provided a business update.</description>
</item>
<item>
<title>Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-announces-addition-of-md-anderson-cancer-center-as-clinical-site-for-phase-12-trial-of-atr-04-targeting-egfri-associated-skin-rash</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-announces-addition-of-md-anderson-cancer-center-as-clinical-site-for-phase-12-trial-of-atr-04-targeting-egfri-associated-skin-rash</guid>
<pubDate>Tue, 24 Feb 2026 13:00:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04 (ATR04-484). ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash.</description>
</item>
<item>
<title>Azitra, Inc. to Present at BIO Investment & Growth Summit</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-to-present-at-bio-investment-and-growth-summit</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-to-present-at-bio-investment-and-growth-summit</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at the BIO Investment & Growth Summit taking place in Miami Beach, Florida, March 2-3, 2026.</description>
</item>
<item>
<title>Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-announces-adjournment-of-special-meeting-and-information-for-reconvened-special-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-announces-adjournment-of-special-meeting-and-information-for-reconvened-special-meeting</guid>
<pubDate>Fri, 06 Feb 2026 21:15:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its Special Meeting scheduled for and convened on February 6, 2026, (the "Special Meeting") has been adjourned until March 6, 2026, at 11:00 a.m. Eastern Time (the "Reconvened Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy s</description>
</item>
<item>
<title>Azitra, Inc. to Present at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-to-present-at-biotech-showcase-alongside-the-jp-morgan-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-to-present-at-biotech-showcase-alongside-the-jp-morgan-annual-healthcare-conference</guid>
<pubDate>Wed, 07 Jan 2026 13:00:00 GMT</pubDate>
<description>Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at Biotech Showcase™ taking place in San Francisco, January 12-14, 2026.</description>
</item>
<item>
<title>Azitra Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-receives-notice-of-acceptance-of-the-listing-standards-compliance-plan-from-nyse-american</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-receives-notice-of-acceptance-of-the-listing-standards-compliance-plan-from-nyse-american</guid>
<pubDate>Wed, 17 Dec 2025 21:10:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Azitra's plan (the "Plan") to come into compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. As previously reported, on October 1, 2025, Azitra received a letter from the NYSE America</description>
</item>
<item>
<title>Azitra, Inc. Announces Pricing of $1.5 Million Private Placement Priced At a Premium To Market Under NYSE Rules</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-announces-pricing-of-dollar15-million-private-placement-priced-at-a-premium-to-market-under-nyse-rules</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-announces-pricing-of-dollar15-million-private-placement-priced-at-a-premium-to-market-under-nyse-rules</guid>
<pubDate>Mon, 24 Nov 2025 14:00:00 GMT</pubDate>
<description>Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,687,500 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 4,687,500 shares of common stock, in a private placement priced at a premium to market un</description>
</item>
<item>
<title>Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-announces-q3-2025-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-announces-q3-2025-results-and-provides-business-updates</guid>
<pubDate>Wed, 12 Nov 2025 22:15:00 GMT</pubDate>
<description>Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended September 30, 2025, and provided a business update.</description>
</item>
<item>
<title>Azitra, Inc. Addresses False Report Regarding Sale of Securities</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-addresses-false-report-regarding-sale-of-securities</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-addresses-false-report-regarding-sale-of-securities</guid>
<pubDate>Fri, 07 Nov 2025 11:00:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has come to the Company's attention that a report has been circulated claiming that the Company priced a $44 million registered direct offering. This report is false and should not be relied upon.</description>
</item>
<item>
<title>Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-announces-positive-preclinical-data-for-atr-01-program-designed-to-treat-ichthyosis-vulgaris</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-announces-positive-preclinical-data-for-atr-01-program-designed-to-treat-ichthyosis-vulgaris</guid>
<pubDate>Mon, 20 Oct 2025 12:02:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis Whitfill, PhD, MPH, will present positive preclinical progress for its ATR-01 program, targeting the treatment of ichthyosis vulgaris, a disease caused by missing or abnormal filaggrin levels. The detailed data will be presented virtually to the BIO-Europe® conference, which is being</description>
</item>
<item>
<title>Azitra to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-to-participate-in-dermatologic-rare-disease-panel-at-maxim-growth-summit</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-to-participate-in-dermatologic-rare-disease-panel-at-maxim-growth-summit</guid>
<pubDate>Wed, 15 Oct 2025 20:05:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Travis Whitfill Ph.D., Co-Founder and Chief Operating Officer will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit, which is being held at the Hard Rock Hotel in New York City, October 22-23, 2025.</description>
</item>
<item>
<title>Azitra Receives Notice of Non-Compliance from NYSE American</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-receives-notice-of-non-compliance-from-nyse-american</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-receives-notice-of-non-compliance-from-nyse-american</guid>
<pubDate>Fri, 03 Oct 2025 20:45:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Azitra was not in compliance with the Exchange's continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide. Section 1003(a)(ii) requires a listed company to have stockholders' equity of $4 million or more if the listed compan</description>
</item>
<item>
<title>Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference</guid>
<pubDate>Thu, 04 Sep 2025 12:10:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis Whitfill PhD MPH, will deliver a virtual presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City.</description>
</item>
<item>
<title>Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-announces-first-patient-dosed-in-phase-12-trial-for-atr-04-program-targeting-oncology-patients-with-egfri-associated-rash</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-announces-first-patient-dosed-in-phase-12-trial-for-atr-04-program-targeting-oncology-patients-with-egfri-associated-rash</guid>
<pubDate>Wed, 27 Aug 2025 12:10:00 GMT</pubDate>
<description>Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the dosing of the first patient in its Phase 1/2 clinical trial of ATR04-484, a topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in</description>
</item>
<item>
<title>Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-announces-q2-2025-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-announces-q2-2025-results-and-provides-business-updates</guid>
<pubDate>Mon, 11 Aug 2025 21:00:00 GMT</pubDate>
<description>Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended June 30, 2025, and provided a business update.</description>
</item>
<item>
<title>Azitra, Inc. Announces Reverse Stock Split</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-inc-announces-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-inc-announces-reverse-stock-split</guid>
<pubDate>Mon, 11 Aug 2025 20:15:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 6.66 pre-split shares. The reverse stock split will become effective at 12:01 A.M. Eastern Time, on August 21, 2025. The Company's common stock will continue to be traded on the NYSE American under the symbol "AZTR" and will</description>
</item>
<item>
<title>Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome</title>
<link>https://6ix.com/company/azitra-inc/news/azitra-reports-promising-safety-data-from-phase-1b-trial-in-netherton-syndrome</link>
<guid isPermaLink="true">https://6ix.com/company/azitra-inc/news/azitra-reports-promising-safety-data-from-phase-1b-trial-in-netherton-syndrome</guid>
<pubDate>Tue, 17 Jun 2025 12:02:00 GMT</pubDate>
<description>Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced encouraging safety data from the initial clinical trial of its live biotherapeutic candidate, ATR12-351, targeting Netherton syndrome.</description>
</item>
</channel>
</rss>